ADVICENNE overview

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC) today announced the appointment of Peter Meeus as Chief Executive Officer of Advicenne, effective February 15, 2021 . Dr. André Ulmann, who has been serving as interim CEO, will assume the position of Chief Medical Officer of the Company. “ I am very pleased to welcome Peter Meeus as our new CEO. Peter brings an extensive background as a leader in healthcare and has an impressive track record in execution and value...

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC) today announces the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of its lead product ADV7103 (Sibnayal®) as therapy for distal renal tubular acidosis (dRTA). The European Commission (EC) will now review the CHMP recommendation and a final decision on the Marketing Authorisation of ADV7103 in the European Union is expected in the...

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC) today announces the signature of a €4.3 million credit agreement, guaranteed by the French State, with banking partners BNP Paribas and BPI France. This loan, in the form of a State-guaranteed loan in the context of the COVID-19 pandemic, contributes to strengthening the Company's cash position. The loan is 90% guaranteed by the French State with an initial maturity of 12 months and an extension option of up to 5 years,...

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC) today announced the publication of its financial results for the six months ending on June 30, 2020, and provided an update on the company’s activities and outlook. In a statement, Chief Executive Officer Dr. André Ulmann reflected on the company’s achievements in the difficult context of the COVID-19 health crisis, providing an overview of future developments and thanking the Advicenne team for its dedication: “During...

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) today announced the reception of the first tranche of this loan, in the amount of €7.5 million. This drawdown implements the loan agreement with the European Investment Bank, signed in July 2019. This totally non-dilutive financing is structured in three tranches of €7.5 million, €5 million and €7.5 million. Its aim is to finance Advicenne’s growth and support the company’s research and development strategy as well as...

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC)(Euronext: ADVIC) to provide an update on its ongoing activities and its management of the COVID-19 crisis during the company’s May 26 combined shareholders meeting, to take place behind closed doors as a consequence of the pandemic. Advicenne demonstrated its resilience during the COVID-19 pandemic. Already accustomed to telecommuting prior to the crisis, the company has been able to pursue its activity with a minimum impact thanks to the...

Regulatory news: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC - FR0013296746), a biopharmaceutical company specializing in the development of adult and pediatric therapeutic products for the treatment of orphan renal and neurological diseases, announces procedures for participation and voting in its May 26 combined shareholders meeting in view of the exceptional context brought about by the novel coronavirus (COVID-19). In compliance with government restrictions on public gatherings and...

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext Paris & Brussels: ADVIC - FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney diseases, today announced its financial results for the year ended December 31, 2019 and confirmed its 2020 operational outlook. 2019 Highlights 2019 was a year of significant development for Advicenne as the company approaches the European commercialization of its lead...

Regulatory News: Advicenne (Euronext Paris & Brussels: ADVIC - FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for orphan renal and neurological diseases, today announces that Dr Luc-André Granier has left his role as CEO of the Company. The Board of Directors has elected Dr. André Ulmann, current Board Observer of the company, as Interim CEO of Advicenne, with immediate effect. David Horn Solomon, Chairman of the...

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext Paris & Brussels: ADVIC - FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney diseases, today announced that it has made its lead drug candidate, ADV7103, available for use within the framework of the Temporary Authorization for Use (TAU) scheme established by France’s National Agency of Medicine and Health Products Safety ( Agence Nationale de...

Regulatory News: Advicenne (Euronext: ADVIC - FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney disease, today published its indicative financial calendar for the year 2020. Event Date* Annual results 2019 Friday, March 13, 2020 General Meeting Tuesday, May 26, 2020 Half-Year Results 2020 Friday, September 25, 2020 Financial year end on December 31 * Subject to change. Publication before market opens. About...

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext : ADVIC - FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney disease, today announced that its lead drug candidate, ADV7103, has been granted orphan drug designation by the European Medicines Agency (EMA) for the treatment of cystinuria in Europe. “The EMA’s positive opinion regarding orphan drug designation for ADV7103 is of significant...

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC - FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney disease, today announces the publication of its 2019 half-year financial report. This report is available in electronic version on the Company's website ( www.advicenne.com ) under the section ‘Investors’. About Advicenne Advicenne (Euronext - ADVIC) is dedicated to developing and...

Advicenne / Key word(s): Miscellaneous Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris 08-Apr-2019 / 17:45 CET/CEST Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris Nîmes, France, April 8, 2019 (5:45 p.m. CET) Advicenne is a specialty pharmaceutical company dedicated to patients suffering from rare and neglected diseases. The company has already started selling products but its flagship drug candidate, ADV7103, is currently pending European marketing...